Citation Impact
Citing Papers
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
2013 Standout
The MR-Base platform supports systematic causal inference across the human phenome
2018 Standout
Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials.
1990
Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis
2007 Standout
HMG-CoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trials data
1998
Completeness of reporting trial results: effect on physicians' willingness to prescribe
1994
Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels
1998 Standout
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
2011 Standout
Differential Effects of Lipid-Lowering Therapies on Stroke Prevention
2003
Rethinking amide bond synthesis
2011 StandoutNature
By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?
1994
The Metabolic Syndrome and Total and Cardiovascular Disease Mortality in Middle-aged Men
2002 Standout
Selected major risk factors and global and regional burden of disease
2002 Standout
Aspirin plus Clopidogrel as Secondary Prevention after Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis
2014 Standout
2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults
2009 Standout
Coronary heart disease: seven dietary factors
1991 Standout
Distinct efficacy of HIV-1 entry inhibitors to prevent cell-to-cell transfer of R5 and X4 viruses across a human placental trophoblast barrier in a reconstitution model in vitro
2008 StandoutNobel
Severe Sepsis and Septic Shock
2013 Standout
Relation of coronary heart disease incidence and total mortality to plasma cholesterol reduction in randomised trials: use of meta-analysis
1993
Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs
2007 Standout
Antioxidants and Atherosclerotic Heart Disease
1997 Standout
Efficacy of Valganciclovir in the Treatment of Cytomegalovirus Disease in Kidney and Pancreas Transplant Recipients
2006
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
2010 Standout
Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: The cholesterol and recurrent events trial (CARE)
1991
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration
2009 Standout
Cholesterol Reduction in Cardiovascular Disease — Clinical Benefits and Possible Mechanisms
1995
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial
2003 Standout
Explaining the Decrease in U.S. Deaths from Coronary Disease, 1980–2000
2007 Standout
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial
2002 Standout
The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels
1996 Standout
Randomized, Controlled Trials, Observational Studies, and the Hierarchy of Research Designs
2000 Standout
Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children
2012
A Computationally Designed Hemagglutinin Stem-Binding Protein Provides In Vivo Protection from Influenza Independent of a Host Immune Response
2016 StandoutNobel
Discontinuation of Antihyperlipidemic Drugs — Do Rates Reported in Clinical Trials Reflect Rates in Primary Care Settings?
1995
Pharmacology of estrogens and progestogens: influence of different routes of administration
2005
Effects of statins on stroke prevention in patients with and without coronary heart disease: A meta-analysis of randomized controlled trials
2004
Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes
2004
Infection in Solid-Organ Transplant Recipients
2007 Standout
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration
2009 Standout
Synthetic therapeutic peptides: science and market
2009
Atherosclerosis
2001 Standout
Projected life-expectancy gains with statin therapy for individuals with elevated c-reactive protein levels
2002
Protein therapeutics: a summary and pharmacological classification
2007 Standout
External validity of randomised controlled trials: “To whom do the results of this trial apply?”
2005 Standout
Reduction of Serum Cholesterol with Sitostanol-Ester Margarine in a Mildly Hypercholesterolemic Population
1995 Standout
Bias in meta-analysis detected by a simple, graphical test
1997 Standout
Transport of Peptidomimetic Drugs by the Intestinal Di/tri‐peptide Transporter, PepT1
2002
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
2009 Standout
The use of antiviral agents for the management of severe influenza
2010
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
2013 Standout
Dissecting racial bias in an algorithm used to manage the health of populations
2019 StandoutScience
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2019 Standout
Systematic Review on the Risk and Benefit of Different Cholesterol-Lowering Interventions
1999
Clinical Application of C-Reactive Protein for Cardiovascular Disease Detection and Prevention
2003 Standout
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
2004 Standout
Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels
1998 Standout
Quantitative Synthesis in Systematic Reviews
1997 Standout
Guidelines for the Primary Prevention of Stroke
2014 Standout
Systematic Reviews: Synthesis of Best Evidence for Clinical Decisions
1997 Standout
Neuraminidase inhibitors for preventing and treating influenza in adults and children
2014
Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths
2007 Standout
Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions
2016
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
2009 Standout
Cholesterol Reduction Yields Clinical Benefit
1998
MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial
2003 Standout
Cholesterol lowering trials in coronary heart disease: frequency of citation and outcome.
1992
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials
2012 Standout
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
2004 Standout
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
2011 Standout
Epidemiology of coronary heart disease: The Framingham study
1984
CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials
2010 Standout
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial
2002 Standout
Cholesterol Reduction Yields Clinical Benefit
1995
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins
2005 Standout
Complexity and contradiction in clinical trial research
1987
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2019 Standout
Works of Albert Dorr being referenced
Lack of Interaction between Enfuvirtide and Ritonavir or Ritonavir‐Boosted Saquinavir in HIV‐1‐Infected Patients
2004
Pharmacokinetics of norethindrone: Effect of particle size
1989
Single‐Dose Pharmacokinetics of Valganciclovir in HIV‐ and CMV‐Seropositive Subjects
1999
The Pharmacokinetics and Tolerability of the Oral Neuraminidase Inhibitor Oseltamivir (Ro 64–0796/GS4104) in Healthy Adult and Elderly Volunteers
2000
Colestipol hydrochloride in hypercholesterolemic patients—Effect on serum cholesterol and mortality
1978
Lack of Pharmacokinetic Interaction between the Oral Anti-Influenza Prodrug Oseltamivir and Aspirin
2002
Pharmacokinetics of plasma enfuvirtide after subcutaneous administration to patientswith human immunodeficiency virus: Inverse Gaussian density absorption and 2‐compartment disposition*
2002
Assessment of Metabolic Inhibition Potential of Enfuvirtide Using a 5‐Drug Cocktail in HIV‐1 Infected Patients
2003